Results for tag: "Induced Myeloid Leukemia Drug"

Induced Myeloid Leukemia (IML) is a type of cancer that affects the bone marrow and blood cells. It is a form of acute myeloid leukemia (AML) and is caused by the abnormal growth of myeloid cells. Treatment for IML typically involves chemotherapy, radiation therapy, and/or stem cell transplantation. In recent years, drug therapies have become increasingly important in the treatment of IML. These drugs target specific proteins and pathways involved in the development and progression of the disease. The IML drug market is highly competitive, with a number of companies developing and marketing drugs for the treatment of IML. These companies include Novartis, Celgene, Pfizer, Merck, and Bristol-Myers Squibb. These companies are actively researching and developing new drugs to improve the treatment of IML, as well as exploring new combinations of existing drugs to improve patient outcomes. Show Less Read more